Free tool
Cell therapy stocks
We cover 7 companies grouped under the Cell therapy theme. The median market value in the group is $34.78M. Across the group, the median move over the past trading day is +1.38%. Price change over the past year runs from −54.7% to +44.8% across the middle 80 percent of the group, with a median of −27.7%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
7 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| ALCLS.PA | Cellectis S.A. | 2.94 EUR | +16.59% | −30.30% | +27.74% |
| V3V.DE | FamiCord AG | 2.86 EUR | +0.70% | −52.73% | −61.35% |
| HEMO.L | Hemogenyx Pharmaceuticals Plc | 588.00 GBP | −8.12% | +3.52% | +70.43% |
| PTG.WA | Poltreg S.A. | 25.00 PLN | +9.17% | −1.96% | −14.68% |
| PSH0.DE | Sernova Biotherapeutics Inc | 0.08 EUR | +14.41% | −2.99% | −27.68% |
| F98.F | CytoMed Therapeutics Limited | 0.84 EUR | +12.08% | −73.06% | −50.30% |
| BSFA.L | BSF Enterprise Plc | 1.15 GBP | +43.75% | −39.47% | −48.89% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.